An experimental vaccine developed to prevent corona virus in China has appeared safe in the final stages of human testing.
This was revealed in the preliminary results of the final phase of the clinical trial of this experimental vaccine of the Chinese company Synovik Biotech in Brazil.
Synovik is the first company in the world to release the results of a final-stage trial, putting China ahead of the rest of the world in developing a vaccine to prevent the corona virus.
Preliminary results from the final phase of the human trial of the vaccine, Corona Week, were released by the Botany Institute in Brazil.
Read More:The potential cost of the soon to be available corona vaccine has been revealed
The institute is working on the third phase of human trials of the vaccine in Brazil and says that 9,000 volunteers have been shown to use two doses of the experimental vaccine.
But Brazilian researchers say data on how effective the vaccine is in protecting people against the new corona virus will not be released until it is tested on all 15,000 volunteers in extended trials. Is not done.
Sao Paulo state health secretary Jean Gorchetian said the vaccine produces seemingly protective antibodies and is expected to be regulated by the end of this year and made available to the public in early 2021. Will start using.
Due to the limited number of coronavirus cases in China, the third phase of the experimental vaccine is being tried by Brazil in Brazil, one of the few large countries infected with the coronavirus.
Synovik is also building a new plant in Beijing that will produce 300 million doses of the virus annually.
In China, this experimental vaccine is being provided to key workers and high-risk groups at a cost of 200 Chinese Yuan (4851 Pakistani rupees) per dose under the national program, and each individual will be given 2 doses, ie 400 Yuan (9 More than 1,700 Pakistani rupees).
It is the first Chinese vaccine to be priced, while the final phase of the vaccine is being tested in Brazil as well as Indonesia and Turkey.
The final trial of the Oxford University vaccine is also nearing completion, but it is not yet clear when the results will be released.
Read More:Negative results on volunteers, trial phase of corona vaccine stopped
The US company Pfizer also said that the preliminary results of its trial could be released this month, while the results of the final trial of another US company Moderina’s vaccine are likely to be released in November.
Pfizer and Moderina have hired almost all of the volunteers involved in the final phase.
Pfizer has so far trained 38,000 of the 40,000 to be part of the vaccine trial, compared to 30,000 volunteers for the Moderina trial, and only a few hundred remain.
The results of its coronavirus vaccine could also be released next month by Russia’s Gamalia Institute.
In June, Synovic Biotech Limited released the results of the first and second phases of its human vaccine trial.
According to a statement issued by the Beijing-based company on the occasion, the human trial did not have any serious side effects from the vaccine, which has been dubbed Corona Week, and those who were given it two weeks later. There was a strong immune response to the virus, including antibodies needed to neutralize the virus.
The company involved 743 healthy people between the ages of 18 and 59 in these phases.
143 people were included in the first phase while 600 people were included in the second phase.
These individuals were given 2 schedules of vaccine dose or a placebo (a harmless substance given as medicine).
The people who were vaccinated had more than 90% levels of antibodies to the virus after 14 days, but no serious side effects were seen.
The vaccine uses a variant of the corona virus and is one of five experimental vaccines from China that have entered the final stages of human testing, after which general use will be approved.
China announced in September that millions of citizens have so far been given two experimental vaccines that are currently undergoing the third phase of clinical trials.
Read More:The corona vaccine will be ready by the end of the year,World Health Organization
CNBG Secretary Zhao Song told China National Radio that no one using the vaccine had any side effects, nor was anyone infected with the code.
He also said that the vaccine could protect a person from corona virus for up to three years.
“The results of animal experiments and other research indicate that vaccine protection can last for one to three years,” he said.
In August, China said vaccines to prevent code 19 would be approved only if their efficacy rate was at least 50 percent and immunity against the corona virus was maintained for six months. Will
A draft proposed by China’s Center for Drug Evolution (CCDE) has come up with regulations regarding the corona vaccine.
According to the draft, there is a minimum efficacy rate for vaccines for emergency use and this will include vaccines that have not completed a clinical trial but will be approved for use based on their efficacy.